Specialized Proresolving Mediators for Therapeutic Interventions Targeting Metabolic and Inflammatory Disorders
Open Access
- 1 September 2021
- journal article
- review article
- Published by The Korean Society of Applied Pharmacology in Biomolecules & Therapeutics
- Vol. 29 (5), 455-464
- https://doi.org/10.4062/biomolther.2021.094
Abstract
Uncontrolled inflammation is considered the pathophysiological basis of many prevalent metabolic disorders, such as nonalcoholic fatty liver disease, diabetes, obesity, and neurodegenerative diseases. The inflammatory response is a self-limiting process that produces a superfamily of chemical mediators, called specialized proresolving mediators (SPMs). SPMs include the omega-3-derived family of molecules, such as resolvins, protectins, and maresins, as well as arachidonic acid-derived (omega-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, and alleviation of pain and promote tissue regeneration via novel mechanisms. SPMs function by binding and activating G protein-coupled receptors, such as FPR2/ALX, GPR32, and ERV1, and nuclear orphan receptors, such as ROR alpha. Recently, several studies reported that SPMs have the potential to attenuate lipid metabolism disorders. However, the understanding of pharmacological aspects of SPMs, including tissue-specific biosynthesis, and specific SPM receptors and signaling pathways, is currently limited. Here, we summarize recent advances in the role of SPMs in resolution of inflammatory diseases with metabolic disorders, such as nonalcoholic fatty liver disease and obesity, obtained from preclinical animal studies. In addition, the known SPM receptors and their intracellular signaling are reviewed as targets of resolution of inflammation, and the currently available information on the therapeutic effects of major SPMs for metabolic disorders is summarized.Keywords
Funding Information
- National Research Foundation of Korea (2021R1C1C1004023, NRF-2019R1C1C1002014, 2017R1A2B3011870, 2018R1A5A2024425)
- Kangwon National University
This publication has 74 references indexed in Scilit:
- Resolvin D1 attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving the PPARγ/NF-κB pathwayRespiratory Research, 2012
- Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediatorsBlood, 2012
- Resolvin D1 Receptor Stereoselectivity and Regulation of Inflammation and Proresolving MicroRNAsThe American Journal of Pathology, 2012
- Resolvin D1 and Its Precursor Docosahexaenoic Acid Promote Resolution of Adipose Tissue Inflammation by Eliciting Macrophage Polarization toward an M2-Like PhenotypeThe Journal of Immunology, 2011
- Inflammatory links between obesity and metabolic diseaseJCI Insight, 2011
- Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese‐diabetic miceThe FASEB Journal, 2011
- Docosahexaenoic Acid-Derived Neuroprotectin D1 Induces Neuronal Survival via Secretase- and PPARγ-Mediated Mechanisms in Alzheimer's Disease ModelsPLOS ONE, 2011
- GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing EffectsCell, 2010
- Obesity‐induced insulin resistance and hepatic steatosis are alleviated by ω‐3 fatty acids: a role for resolvins and protectinsThe FASEB Journal, 2009
- Expression of 5-lipoxygenase and leukotriene A 4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instabilityProceedings of the National Academy of Sciences of the United States of America, 2006